Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

You may be eligible if

• Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration.
• Baseline mean hemoglobin \< 10.0 g/dL (untransfused) and/or be transfusion dependent defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline.
• More than 30 days must have elapsed since any previous treatment for MDS, other than transfusion.
• Women must not be pregnant or lactating
• No use of another experimental study drug within 30 dy\\ays of baseline
• Understand and sign written informed consent
• Able to adhere to study visit schedule, understand and comply with other protocol requirements.